Literature DB >> 14551701

Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Hong-Liang Li1, De-Pei Liu, Chih-Chuan Liang.   

Abstract

The paraoxonase (PON) gene cluster contains at least three members, including PON1, PON2, and PON3, located on chromosome 7q21.3-22.1. Until now there has been little insight into the role of the respective gene products in human physiology and pathology. However, emerging evidence from biochemical and genetic experiments is providing clues about the role(s) of the products of these genes, which indicates that PON(s) acts as important guardians against cellular damage from toxic agents, such as organophosphates, oxidized lipids in the plasma low-density lipoproteins. In parallel, substantial data have been published on the association between the polymorphisms of PON(s) and coronary heart disease. It has become clear that the polymorphisms significantly affect the prevalence of coronary heart disease. However, the associations between the PON(s) polymorphisms and most of these conditions were found to be inconsistent when additional populations were investigated. This contribution provides an overview of the status of research of each of the three genes and the available association studies and the potential problems in interpreting the data. We also review the current evidence on the association between PON(s) polymorphisms and diseases other than coronary heart disease and some metabolic quantitative phenotypes, such as plasma lipoproteins, plasma glucose, and birthweight. Finally, we suggest directions for the future that might elucidate the role of the PON genetic polymorphisms in this potentially important function of PON(s) and the role in coronary heart disease and other related diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551701     DOI: 10.1007/s00109-003-0481-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  99 in total

Review 1.  Paraoxonase genes and disease.

Authors:  R A Hegele
Journal:  Ann Med       Date:  1999-06       Impact factor: 4.709

2.  The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors.

Authors:  Michelle M Murphy; Elisabet Vilella; Santiago Ceruelo; Lidia Figuera; Marta Sanchez; Jordi Camps; Gemma Cuco; Natàlia Ferré; Antonio Labad; Natasha Tasevska; Victoria Arija; Jorge Joven; Joan Fernandez-Ballart
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

3.  Comment--to: Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase 2 polymorphisms are associated with diabetic nephropathy in Type II diabetes. Diabetologia 44: 104-107.

Authors:  L H Canani; S Araki; J H Warram; A S Krolewski
Journal:  Diabetologia       Date:  2001-08       Impact factor: 10.122

4.  Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study.

Authors:  N Watzinger; H Schmidt; M Schumacher; R Schmidt; B Eber; F M Fruhwald; R Zweiker; G M Kostner; W Klein
Journal:  Cardiology       Date:  2002       Impact factor: 1.869

5.  Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids.

Authors:  S T Reddy; D J Wadleigh; V Grijalva; C Ng; S Hama; A Gangopadhyay; D M Shih; A J Lusis; M Navab; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

6.  Paraoxonase2 polymorphisms are associated with nephropathy in Type II diabetes.

Authors:  M Pinizzotto; E Castillo; M Fiaux; E Temler; R C Gaillard; J Ruiz
Journal:  Diabetologia       Date:  2001-01       Impact factor: 10.122

7.  Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus.

Authors:  O Kordonouri; R W James; B Bennetts; A Chan; Y L Kao; T Danne; M Silink; K Donaghue
Journal:  Metabolism       Date:  2001-06       Impact factor: 8.694

8.  Expression of human paraoxonase (PON1) during development.

Authors:  Toby B Cole; Rachel L Jampsa; Betsy J Walter; Tara L Arndt; Rebecca J Richter; Diana M Shih; Aaron Tward; Aldons J Lusis; Rhona M Jack; Lucio G Costa; Clement E Furlong
Journal:  Pharmacogenetics       Date:  2003-06

9.  Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women.

Authors:  Maire Rantala; Marja-Leena Silaste; Anu Tuominen; Jari Kaikkonen; Jukka T Salonen; Georg Alfthan; Antti Aro; Y Antero Kesäniemi
Journal:  J Nutr       Date:  2002-10       Impact factor: 4.798

10.  Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites.

Authors:  A P Boright; P W Connelly; J H Brunt; S W Scherer; L C Tsui; R A Hegele
Journal:  Atherosclerosis       Date:  1998-07       Impact factor: 5.162

View more
  57 in total

Review 1.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

2.  Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli.

Authors:  Rachel Nadif; Margaret Mintz; Anne Jedlicka; Jean-Pierre Bertrand; Steven R Kleeberger; Francine Kauffmann
Journal:  Free Radic Res       Date:  2005-12

3.  Paraoxonase 1, 2 and 3 DNA variants and susceptibility to childhood inflammatory bowel disease.

Authors:  R Sanchez; E Levy; E Seidman; D Amre; F Costea; D Sinnett
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

Review 4.  Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children's environmental health.

Authors:  Nina Holland; Daneida Lizarraga; Karen Huen
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

5.  Paraoxonase 1 L55M, Q192R and paraoxonase 2 S311C alleles in atherothrombosis.

Authors:  L Cozzi; J Campolo; M Parolini; R De Maria; M C Patrosso; A Marocchi; O Parodi; S Penco
Journal:  Mol Cell Biochem       Date:  2012-12-06       Impact factor: 3.396

6.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.

Authors:  Tamali Bhattacharyya; Stephen J Nicholls; Eric J Topol; Renliang Zhang; Xia Yang; David Schmitt; Xiaoming Fu; Mingyuan Shao; Danielle M Brennan; Stephen G Ellis; Marie-Luise Brennan; Hooman Allayee; Aldons J Lusis; Stanley L Hazen
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

7.  Lipid and lipoprotein profiles among middle aged male smokers: a study from southern India.

Authors:  Ramachandran Meenakshisundaram; Chinnasamy Rajendiran; Ponniah Thirumalaikolundusubramanian
Journal:  Tob Induc Dis       Date:  2010-10-05       Impact factor: 2.600

8.  Molecular dynamics simulation of human serum paraoxonase 1 in DPPC bilayer reveals a critical role of transmembrane helix H1 for HDL association.

Authors:  Mahesh Chandra Patra; Surya Narayan Rath; Sukanta Kumar Pradhan; Jitendra Maharana; Sachinandan De
Journal:  Eur Biophys J       Date:  2013-12-03       Impact factor: 1.733

9.  Localization of multiple pleiotropic genes for lipoprotein metabolism in baboons.

Authors:  David L Rainwater; Laura A Cox; Jeffrey Rogers; John L VandeBerg; Michael C Mahaney
Journal:  J Lipid Res       Date:  2009-03-08       Impact factor: 5.922

10.  Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms.

Authors:  Karen Huen; Kim Harley; Jordan Brooks; Alan Hubbard; Asa Bradman; Brenda Eskenazi; Nina Holland
Journal:  Environ Health Perspect       Date:  2009-06-09       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.